Vivek Vishnudas
Chief Technology Officer, Head of Research & Development Site BPGBio Inc.
Dr. Vivek Vishnudas oversees the development of experimental therapeutics from conception and drug discovery to IND filing and First-in-Human studies. Drug-discovery programs are based on the novel disease targets/phenotype identified with Interrogative Biology®. Dr. Vishnudas leads an interdisciplinary team of drug-discovery scientists, biochemists and DMPK scientists to understand target tractability & pharmacology. Dr. Vishnudas manages the external R&D collaboration with industrial and academic partners and aims to scale up BPGbio’s R&D therapeutics portfolio. He is a co-inventor of the Interrogative Biology® technology, and inventor of E2 Based Induced Proximity Platfroms. His breadth of operations covers scientific leadership, strategic R&D initiatives, and intellectual property strategies.
Seminars
- Leveraging AI-driven biology discovery to identify ubiquitin-conjugating enzymes (E2s) as novel therapeutic target
- Demonstrating a unique mechanism of action by locking ubiquitin to E2 enzymes, preventing discharge, inhibiting enzyme function, and triggering autophagy to clear mutant huntingtin
- Advancing lead optimization efforts with the goal of progressing to animal proof-ofconcept studies for neurodegenerative proteinopathies
